Английская Википедия:Idalopirdine

Материал из Онлайн справочника
Версия от 02:24, 25 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451553711 | IUPAC_name = 2-(6-Fluoro-1''H''-indol-3-yl)-''N''-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine | image = Lu-AE58054.svg <!--Clinical data--> | tradename = | pregnancy_category = | legal_status = | routes_of_administration = <!--Pharmacokinetic da...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials failed too, the company confirmed in early 2017.[3]

See also

References

Шаблон:Reflist

External links

Шаблон:Antidementia

Шаблон:Serotonergics Шаблон:Tryptamines